Key statistics
As of last trade, Crinetics Pharmaceuticals Inc (CRNX:NSQ) traded at 39.47, 63.78% above the 52 week low of 24.10 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 39.67 |
|---|---|
| High | 40.35 |
| Low | 39.03 |
| Bid | 39.20 |
| Offer | 39.55 |
| Previous close | 40.68 |
| Average volume | 905.40k |
|---|---|
| Shares outstanding | 104.71m |
| Free float | 92.76m |
| P/E (TTM) | -- |
| Market cap | 4.26bn USD |
| EPS (TTM) | -4.94 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 15:28 GMT.
More ▼
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
- Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
- Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
- Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
- Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
More ▼
